Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA.
Parasit Vectors. 2023 Nov 27;16(1):440. doi: 10.1186/s13071-023-05946-3.
Compliant ectoparasiticide product use is a comprehensive way to control ticks and reduce the risk of tick-borne pathogen transmission to dogs. Because the systemically acting isoxazoline ectoparasiticides require tick attachment for drug delivery, fast speed of kill is essential to minimize tick-borne pathogen transmission risk.
Dogs of satisfactory tick-carrying capacity were randomly allocated to treatment groups and administered, per label instructions, Bravecto Chews (minimum 25 mg/kg fluralaner), Simparica TRIO (minimum 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel), or no treatment. Dogs were infested with approximately 50 unfed adult (35 female, 15 male) Ixodes scapularis on Day -2, 21 and 28. Live tick counts were performed at 4, 8, 12 and 24 h post-treatment (Day 0) and post-infestation on Day 21 and 28. Tick control efficacy was determined by comparing live tick means for each product-treated group to the untreated control group and each other at all time points using a linear mixed model. The percent of dogs free of live ticks was analyzed using the Fisher's exact test for treatment group comparison.
The untreated control group maintained adequate tick infestations throughout the study. Using geometric means, an existing I. scapularis infestation was controlled by 99.7% and 93.0% 12 h post-treatment and by 100% and 99.5% 24 h post-treatment, for Bravecto and Simparica TRIO-treated dogs, respectively. Ixodes scapularis infestations were controlled more quickly for Bravecto- compared to Simparica TRIO-treated dogs on Day 21 at 8 h (efficacy 74.0% vs. 0.0%, p = 0.003) and 12 h (efficacy 99.2% vs. 39.4%, p < 0.001) post-infestation and Day 28 at 8 h (efficacy 92.2% vs. 0.0%, p < 0.001) and 12 h (efficacy 99.6% vs. 27.7%, p < 0.001) post-infestation. On Day 28 post-treatment, the efficacy of Bravecto and Simparica TRIO to control a new I. scapularis infestation was 100% and 96.6%, respectively, by 24 h post-infestation. Of product-treated dogs, 100% of Bravecto-treated dogs were free of live ticks by 24 h post-treatment or post-infestation. No treatment-related adverse reactions occurred during the study.
Ixodes scapularis infestations are controlled more quickly 21 and 28 days post-treatment for dogs administered a single dose of Bravecto compared to dogs administered a single dose of Simparica TRIO.
顺从性的杀寄生虫剂产品的使用是控制蜱虫和降低犬类感染蜱传病原体风险的综合方法。由于全身作用的异噁唑啉类杀寄生虫剂需要蜱虫附着以输送药物,因此快速杀灭速度对于最小化蜱传病原体传播风险至关重要。
具有满意的蜱虫携带能力的狗被随机分配到治疗组,并按照标签说明使用博来恩咀嚼片(最低 25mg/kg 氟雷拉纳)、犬心保三方(最低 1.2mg/kg 噻拉菌素、24μg/kg 米尔贝肟、5mg/kg 吡喹酮)或不进行治疗。狗在第-2、21 和 28 天被大约 50 只未进食的成年(35 只雌性,15 只雄性)硬蜱侵染。在治疗后 4、8、12 和 24 小时(第 0 天)以及在第 21 和 28 天侵染后进行活蜱计数。通过线性混合模型,将每个产品治疗组的活蜱虫平均值与未治疗的对照组进行比较,并在所有时间点与彼此进行比较,以确定蜱虫控制效果。使用 Fisher 精确检验对治疗组进行比较,以分析无活蜱虫的犬比例。
未治疗的对照组在整个研究期间保持了足够的蜱虫侵染。使用几何平均值,博来恩和犬心保三方治疗的狗在治疗后 12 小时内将现有的硬蜱侵染控制在 99.7%和 93.0%,在治疗后 24 小时内将其控制在 100%和 99.5%。与犬心保三方治疗的狗相比,博来恩治疗的狗在第 21 天的 8 小时(效力 74.0%对 0.0%,p=0.003)和 12 小时(效力 99.2%对 39.4%,p<0.001)以及第 28 天的 8 小时(效力 92.2%对 0.0%,p<0.001)和 12 小时(效力 99.6%对 27.7%,p<0.001)侵染后,硬蜱侵染被控制得更快。在治疗后第 28 天,博来恩和犬心保三方对新的硬蜱侵染的控制效力在侵染后 24 小时内分别为 100%和 96.6%。在接受产品治疗的狗中,博来恩治疗的狗在治疗后 24 小时或侵染后无活蜱虫的比例为 100%。在研究过程中,没有发生与治疗相关的不良反应。
与犬心保三方治疗的狗相比,博来恩治疗的狗在第 21 和 28 天治疗后硬蜱侵染的控制速度更快。